Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials

被引：0
|
作者：
Treat, J.
Scagliotti, G.
Peng, G.
Monberg, M. J.
Obasaju, C. K.
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e18004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18004
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF PEMETREXED PLUS CISPLATIN WITH OTHER FIRST-LINE DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COMBINED ANALYSIS OF THREE PHASE 3 TRIALS
    Treat, Joseph
    Scagliotti, Giorgio
    Peng, Guangbin
    Pohl, Gerhardt
    Obasaju, Coleman
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S415 - S416
  • [2] Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials
    Treat, Joseph
    Scagliotti, Giorgio V.
    Peng, Guangbin
    Monberg, Matthew J.
    Obasaju, Coleman K.
    Socinski, Mark A.
    [J]. LUNG CANCER, 2012, 76 (02) : 222 - 227
  • [3] FIRST LINE CHEMOTHERAPY WITH PEMETREXED PLUS CISPLATIN IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COMPARISON OF TWO PHASE III TRIALS
    Scagliotti, Giorgio
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dedui, Mircea
    Pujol, Jean-Louis
    Manegold, Christian
    Melemed, Symantha
    John, William
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Melemed, Allen
    Visseren-Grul, Carla
    Paz Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1160 - S1161
  • [4] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [5] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Biesma, B.
    Reck, M.
    San Antonio, B.
    Zimmermann, A. H.
    Visseren-Grul, C.
    Chouaki, N.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [6] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [7] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [8] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
    Scaqliotti, G.
    Park, K.
    Patil, S.
    Rolski, J.
    Gorksel, T.
    Gans, S. J. M.
    Martins, R.
    Visseren-Grul, C.
    Peterson, P.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 363
  • [10] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
12345